Phase I and Phase II Clinical Trials in Progress

• CT267 Phase 1, open-label, multi-center trial of RPT1G in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes/neoplasms Dennise A. de Jesús-Díaz, Aaron Goldberg, Steve Abella, Caroline M. Robb, Michael Schelle, Gregory Crimmins
• CT268 Phase 1 study of ARV-393, a PROTAC BCL6 degrader, as monotherapy in patients with advanced non-Hodgkin lymphoma (NHL) or combined with glofitamab in patients with diffuse large B-cell lymphoma (DLBCL) Martin Hutchings, Andrew Zelenetz, Jacob H. Christensen, Almudena Cascales Hernandez, Sarit Assouline, Luis E. Malpica Castillo, Shalin Kothari, Dipenkumar Modi, Miguel A. Canales Albendea, Damian Cubillas, Alejandro M. Garcia-Sancho, Catherine M. Diefenbach, John Kuruvilla, Paolo F. Caimi, Krish Patel, Sean Landrette, Eric Zhi, Yuanyuan Zhang, Roland Meier, Mathew J. Matasar
• CT269 Point-of-care manufacturing and early clinical evaluation of a tri-specific (CD19/20/22) CAR T-cell therapy for relapsed or refractory (R/R) B-cell malignancies Joseph P. McGuirk, Rupal Soder, Ramesh Balusu, Nathaniel Dudley, Louisa Wirthlin, Tyce Bruns, David Akhavan, Scott J. Weir, Sunil Abhyankar
• CT270 Clinical trial in progress: BCC020 a dose escalation study using difluoromethylornithine (DFMO) and AMXT-1501 followed by a randomized controlled trial of DFMO with or without AMXT-1501 for neuroblastoma, CNS tumors, and sarcomas Giselle Saulnier Sholler, Genevieve Bergendahl, Kevin Bielamowicz, Derek Hanson, Deanna Mitchell, David Hoogstra, Arthur Berg, William Ferguson, Abigail Moore, Jacqueline Kraveka
• CT271 Clinical trial in progress: BCC021 Phase I/II study of Silmitasertib (CX-4945) in combination with chemotherapy in children and young adults with relapsed refractory solid tumors Chandrika Behura, Genevieve Bergendahl, Julie Steinbrecher, Shouhao Zhou, William Ferguson, Jacqueline Kraveka, Kevin Mulieri, Sinisa Dovat, Abigail Moore, Giselle Saulnier Sholler
• CT272 · PDF Clinical trial in progress: BCC022 a phase II trial of tipifarnib and naxitamab for relapsed/refractory neuroblastoma Valerie Brown, Hong-Gang Wang, Genevieve Bergendahl, Arthur Berg, William Ferguson, Jacqueline Kraveka, Abigail Moore, Giselle Saulnier Sholler
• CT273 · PDF FORTE: A phase 2 master protocol assessing plixorafenib for BRAF-altered cancers Elisa Fontana, Macarena I. de la Fuente, Eric Sherman, Rona Yaeger, Malaka Ameratunga, Valentina Gambardella, Jessica Rine, Shubin Shahab, Morgan Winkler, Manish Monga, Dominik Modest, Jeffrey Yachnin, Mehdi Touat, Guillermo de Velasco, Jordi Rodon, Karisa C. Schreck
• CT274 Inhibiting 26S proteosome with sequential bortezomib and temozolomide garners 5 months prolonged survival in recurrent MGMT -negative GBM through amplified tyrosine kinase receptor signaling to avail NF-kB mechanistic target in NCT03643549 Phase IB/II trial Dorota Goplen, Mohummad Aminur Rahman, Surendra Kumar, Marianne H. Hannisdal, Victoria Arnesen, Andreas Waha, Leif Oltedal, Judit Haasz, Jorunn Brekke, Tora S. Solheim, Petter Brandal, Stein A. Lie, Martha Chekenya
• CT275 ALTER: A randomized Phase II trial evaluating an upfront alternating regimen of sacituzumab-govitecan and trastuzumab-deruxtecan versus sacituzumab-govitecan alone in HER2-low metastatic triple-negative breast cancer (NCT07151586) Alexandre de Nonneville, Jean-Marie Boher, Jean-Sébastien Frenel, Gerald Bagoe, Olivier Tredan, Marie-Ange Mouret-Reynier, Chayma Bousrih, Vincent Massard, Julien Grenier, Marie Robert, Florence Lerebours, Delphine Loriat, Florence Dalenc, Christelle Jouannaud, Stéphanie Becourt, Philippe Follana, Sylvain Ladoire, William Jacot, Bogdan-Valentin Popescu, Maxime Brunet, George Emile, Jerôme Lemmonier, Sylvie Mijonnet, Anthony Gonçalves, François Bertucci
• CT276 · PDF PROFFi: A phase II randomized controlled study of fisetin and exercise in postmenopausal breast cancer survivors Samuel Jacob Margolis, Catherine Crespi, Yuliya Zektser, Arman Niknafs, Nikita V. Baclig, Jingran Ji, Mina Sedrak
• CT277 IvoLoC Trial: A phase II trial evaluating the efficacy of ivonescimab in metastatic endocrine refractory HR-positive HER2-negative or triple negative invasive lobular carcinoma (ILC) Jason Mouabbi, Paula Pohlmann, Rachel Layman, Roland Bassett, Lavinia Middleton, Bora Lim, Toni Zaayman, Krystle Nomie, Evgeny Barykin, Anastasiya Evdokimova, Mariana Chavez-MacGregor, Jennifer Litton, Sharon Giordano, Funda Meric-Bernstam
• CT279 · PDF A phase 2 multicohort study to evaluate lorigerlimab (PD-1 x CTLA-4) in participants with advanced solid tumors Helen D. Clark, Kelly M. Rangel, Shawana N. Richard, Jichao Sun, Pepi Pencheva, Chad Hamilton, Amir A. Jazaeri
• CT280 A pragmatic study of the clinical utility of genomic classifiers in guiding prostate cancer treatment decisions: Impact of treatment selection, oncologic outcomes, and treatment-related adverse events (PROMPT-Bx) Brent Mabey, Lauren Lenz, Thaylon Davis, Alexander Gutin, Katherine Johansen Taber, Dale Muzzey, Jeff Jasper, Matthew Schiewer
• CT281 · PDF A phase II trial of ivonescimab for previously treated thymic carcinoma UCLA L-11 Jonathan A. Boiarsky, Chi-hong Tseng, Zhaohui Arter, Matthew Gubens, Chul Kim, Jennifer A. Marks, Surbhi Singhal, Christine Kivork, Larissa Ikenouye, Jonathan W. Goldman
• CT282 · PDF Immune checkpoint inhibitors plus personal dendritic cell vaccines in patients with metastatic melanoma Chaitali S. Nangia, Katrina L. Lopez, Gabriel I. Nistor, Robert O. Dillman
• CT283 Pressurized intraperitoneal aerosolized chemotherapy (PIPAC) in patients with peritoneal-only metastasis from pancreatic ductal adenocarcinoma Julien T. Hohenleitner, Oliver J. Standring, Amber N. Habowski, Murtuza Hassan, Hai Huang, Matthew J. Weiss, Craig E. Devoe, Sepideh Gholami, Arvind Rishi, Daniel A. King, David A. Tuveson, Richard Whelan, Danielle K. Deperalta
• CT284 First-in-human, phase I/II study of BPI-572270, an oral RAS(ON) multi tri-complex inhibitor, in patients with RAS-mutated advanced solid tumors Zhengbo Song, Han Han, Xiang Yang, Wenmao Wu, Jing Guo, Hong Lan, Quan Zhou, Hui Chen, Weijie Li, Pengxiang Wu, Qiuyue Cao, Luyang Zhao, Li Mao, Lieming Ding
• CT285 · PDF Design and rationale of DOMISOL, a first-in-human Phase I/II study of DT-7012 (NCT06819735) in advanced solid tumors Andrew Parsonson, Vineet Kwatra, Prachi Bhave, Azim Khan, Samira El-Farouk, Anne Quesnel, Carolina Duarte, Claire Jouffroy-Zeller, Hélène Muller, David Allman, Abdelkrim Taamma, Ikrame Sahmoudi, Hélène Lelièvre, Mélanie Frauli, Stephan Schann, Nathalie Lenne, Jean-Marie Cuillerot, Vinod Ganju
• CT286 · PDF Toward personalized atezolizumab dosing by therapeutic drug monitoring Hoyoung M. Maeng, Keith T. Schmidt, Michele Reed, Michell Manu, Katherine Lee-Wisdom, Manuk Manukyan, Jennifer L. Marte, Charalampos S. Floudas, Isaac Brownell, Nicholas Tschernia, Fatima Karzai, Hyoyoung Choo-Wosoba, Evrim Turkbey, Ruchi Patel, Lisa Cordes, William D. Figg, James L. Gulley
• CT287 A first-in-human (FIH), Phase 1/2, dose-escalation and dose-optimization study of central nervous system (CNS)-penetrant, PARP1-selective inhibitor EIK1004 in patients with advanced solid tumors with or without brain metastases Timothy A. Yap, Jian Zhang, Yanhua Xu, Sanum Chaudry, Kevin H. Eng, Yawei Zhang, Viola J. Chen, Gerald Falchook
• CT288 · PDF First-in-human study of oral PARG inhibitor SYN608 in advanced solid tumors Jin Li, Xiaohua Wu, Qi Dang, Ke Wang, Zhengbo Song, Jun Zhou, Yujia Zhang, Jian Zhang, Jiajia Li, Weina Shen, Shengjie Yang, Hongli Li, Lu Sun, Liyan Zhou, Jianan Jin, Duo Wu, Yue Xie, Xuzhen Tang, Chao Kan, Song Shi, Hu He, Song Liu, Xiaochun Yu
• CT289 · PDF Phase Ib study of POLQ inhibitor SYN818 combined with olaparib in advanced solid tumors Hongxia Wang, Xiaohua Wu, Min Yan, Jian Zhang, Youzhong Zhang, Yiqun Du, Sai Han, Xiaojun Liu, Jiajia Li, Limin Niu, Duo Wu, Yue Xie, Xuzhen Tang, Chao Kan, Song Shi, Hu He, Song Liu, Xiaochun Yu
• CT290 NTS071-101: A phase 1/2a study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of NTS071 in patients with advanced solid tumors harboring a TP53 Y220C mutation Qiancheng Shen, Yan Xu, Yinqun Wu, Shuhan Shen, Guoqiang Zhou
• CT291 First-in-human study of the IL-12 Prodrug KGX101 demonstrates tumor-microenvironment specific activation, promising antitumor activity, and a manageable safety profile in advanced or metastatic melanoma Jun Guo, Lu Si, Lili Mao, Weidong Jiang, Haixiang Wu, Kahaerjiang Abuduwaili, Yi Zhao, Lianlian Jiang, Yutao Gao, Jiangfeng Fan, Naijun Tang
• CT292 · PDF CAN016, a HER2-targeted dual-payload ADC, phase 1 clinical development Xia G, Fei Tan, Giorgio Massimini, Ying Fan, Shaoshan Wang, Wanping Geng, Sanlong Wang, Yili Yang, Pengqi Xu, Xianyang Chen, Ya Luo, Jiancheng Huang, Henry Ninghui Yu, Binghe Xu
• CT293 · PDF Pilot study of pidnarulex pharmacodynamics in patients with advanced solid tumors Jibran Ahmed, Brian Ko, Sarah J. Shin, Murielle Hogu, Lawrence Rubinstein, Himabindu Gali, Deborah F. Wilsker, Ralph E. Parchment, Laura Kuhlmann, Steven Gore, James H. Doroshow, Alice P. Chen
• CT294 · PDF Phase I study of TROP2 CAR engineered IL-15-transduced cord blood-derived NK cells in advanced solid tumors (TROPIKANA) Oriol Mirallas, David Marin, Hui Chen, Paula Pohlmann, Bora Lim, Mehmet Altan, Samrina Hussain, Amber Kennon, May Daher, Miriam Gavriliuc, Rafet Basar, Wei-Lien Wang, Ying Yuan, Patrow Kebriaei, Elizabeth J. Shpall, Jordi Rodon, David S Hong, Funda Meric-Bernstam, Katy Rezvani, Ecaterina E Dumbrava
• CT295 Phase I trial of CRD3874-SI, a systemically administered third generation allosteric STING agonist, in patients with advanced solid tumors Ciara M. Kelly, Reinhard von Roemeling, Monali Banerjee, Viswatej Avutu, Olayade Babatunde, Lauren Banks, Ping Chi, Mark A. Dickson, Mrinal M. Gounder, Grace Gray, Camron Clark, Mary Louise Keohan, Robert G. Maki, Sujana Movva, Damon Reed, Kelly Schroeder, Li-Xuan Qin, Phillip Wong, Sandip Middya, Ritesh Shrivastava, Debjani Chakraborty, Rajib Ghosh, Sourav Basu, Arjun Surya, William D. Tap, Sandra P. D'Angelo

在完整检索应用中浏览本分会场 →